{"id":7462,"date":"2026-11-14T12:05:00","date_gmt":"2026-11-14T17:05:00","guid":{"rendered":"https:\/\/www.thevoicerealm.com\/blog\/?p=7462"},"modified":"2026-11-14T12:30:55","modified_gmt":"2026-11-14T17:30:55","slug":"pharma-voice-over-side-effects","status":"publish","type":"post","link":"https:\/\/www.thevoicerealm.com\/blog\/pharma-voice-over-side-effects\/","title":{"rendered":"Same Volume, Same Pace: Voicing the Side Effects in a Pharma Ad"},"content":{"rendered":"

This guide is for voice actors who’ve landed, or want to land, a pharmaceutical commercial in the United States. You know the type: a sunny park, a family picnic, a calm voice telling you about a new treatment, and then the part everyone remembers. The side effects.<\/p>\n

For years that section had a reputation as the bit announcers rattled through at speed. That reputation is out of date. There’s a federal rule about how the risk section has to sound, and it lands squarely on the person at the microphone. Here’s what it says, what it means for your read, and how to handle a pharma session without sounding like a different person halfway through the spot.<\/p>\n

The part of the ad with its own rulebook<\/h2>\n

A prescription drug ad on American TV or radio has two jobs. It tells viewers what the drug is for, and it tells them about the most important risks. That second part has a name in the regulations: the major statement.<\/p>\n

Ads don’t have to read the drug’s whole label aloud. Under an option called “adequate provision,” a broadcast ad can give the major statement and then point viewers somewhere else for the full details, such as a website, a phone number, a print ad or their doctor. That’s why you hear lines like “ask your doctor” and “see our ad in this magazine” near the end.<\/p>\n

For a voice actor, the major statement is where the job gets precise. It’s long, it’s packed with medical words, and it’s been checked line by line by lawyers and medical reviewers before it ever reaches you. Nobody wants you improvising here.<\/p>\n

\"Graphic:

\u00a9 The Voice Realm<\/p><\/div>\n

The rule that changed the read<\/h2>\n

In November 2023 the FDA finalised a rule on how the major statement is presented in TV and radio ads. Its title says the risk information has to be presented in a clear, conspicuous and neutral manner. According to the law firm Faegre Drinker, companies had until November 20, 2024 to come into line, and the rule “does not affect the content of a major statement.” It changes how the risks are delivered, not what they are.<\/p>\n

The rule sets five standards, written into the federal regulations at 21 CFR 202.1. Two of them speak straight to voice actors. The first is about the words: the major statement must be “presented in consumer-friendly language and terminology that is readily understandable.”<\/p>\n

The second is about you. The text says the major statement’s “audio information, in terms of the volume, articulation, and pacing used, is at least as understandable” as the audio in the rest of the ad.<\/p>\n

\"A

\u00a9 The Voice Realm<\/p><\/div>\n

Read that again with a voice actor’s ears. Volume, articulation and pacing are the three things a rushed disclaimer read gives away. The risk section can’t get quieter, mumblier or faster than the happy bit before it. The other three standards cover on-screen text and the pictures and music around your read, and they matter to you too, because they change what the session will feel like.<\/p>\n

Same volume, same pace, same person<\/h2>\n

The easiest way to think about it: the risk section is still you, talking to the same person, about something just as important. You’re not switching to a legal voice. You’re just carrying on.<\/p>\n

\n
The old habit<\/span><\/p>\n

The fine print voice<\/h4>\n

The read drops in level, picks up speed and loses its warmth the moment the risks start. Consonants blur. Listeners hear it as the part they’re meant to ignore.<\/p>\n<\/div>\n

The read now<\/span><\/p>\n

One voice, start to finish<\/h4>\n

The risks sound like the rest of the spot: same level, same clear consonants, same unhurried pace. Calm and plain, never grim, never selling. The listener can follow every word.<\/p>\n<\/div>\n<\/div>\n

Here’s what that looks like in practice.<\/p>\n

Keep your level steady.<\/strong> The natural instinct is to drop your volume on bad news. Don’t. If anything, think about lifting your eyeline and talking to someone across a table rather than leaning in to whisper.<\/p>\n

Keep the pace you set at the start.<\/strong> If the benefit section ran at a relaxed, conversational speed, the risk section runs at the same speed. That’s the whole point of the rule. If the copy is too long for the time, that’s a problem for the writers, not something you solve by racing.<\/p>\n

Land every consonant.<\/strong> Drug names, conditions and side effects are full of hard sounds that collapse when you hurry. Clear endings on words like “infections,” “dizziness” and “allergic reactions” are what make the section understandable. If medical words trip you up, our guide to voicing medical narration without tripping on the drug names<\/a> has practice ideas that carry straight over.<\/p>\n

Stay neutral, not grim.<\/strong> “Neutral” works both ways. Don’t make the risks sound scary, and don’t smile through them as if they’re good news. A warm, steady, informative tone is the target. Think of a pharmacist explaining a new prescription to someone they like.<\/p>\n

Don’t sell the risks.<\/strong> The benefit section usually has some lift and optimism in it. The risk section keeps your warmth but drops the sell. If you hear yourself leaning on words to make them sound exciting, back off.<\/p>\n

This is the opposite of the car dealership tag, where speed is part of the style. If you’ve practised reading a legal disclaimer fast without losing a word<\/a>, keep the clarity skills and leave the speed at the door.<\/p>\n

\"A

\u00a9 The Voice Realm<\/p><\/div>\n

Marking up a pharma script<\/h2>\n

Pharma copy rewards preparation more than almost any other commercial script. Do this before you step into the booth.<\/p>\n

Get the pronunciations in writing.<\/strong> The brand name and the generic name will both be in the script, and the client will have a set pronunciation for each. Ask for it, write it phonetically above the word, and say it the same way every time. A brand name said two ways in one spot means a pickup.<\/p>\n

Mark where the risks start.<\/strong> Draw a clear line in the margin at the first word of the major statement. That line is a reminder to yourself: same volume, same pace, same person.<\/p>\n

Plan your breaths.<\/strong> Risk lists are long sentences joined by commas. Find natural places to breathe, between items, not in the middle of a condition’s name. Mark them. Running out of air is how reads speed up without you noticing.<\/p>\n

Group the list.<\/strong> Most major statements group side effects: serious ones, common ones, who shouldn’t take it. Read each group as a small, complete thought. That gives the listener a structure to follow and stops the list turning into a blur.<\/p>\n

Time it at your real pace.<\/strong> Read the whole spot out loud at the pace you’ll use in session and time it. If it comes in long, tell the producer early. A tight script is easier to fix before the session than after the legal team has signed off on your take.<\/p>\n

\"Graphic:

\u00a9 The Voice Realm<\/p><\/div>\n

Working with the agency and the reviewers<\/h2>\n

Pharma sessions tend to be directed, and they tend to have a crowd listening. You might have a creative director, a producer, a client brand team and someone from medical or legal review on the line. That’s normal. It’s not a sign you’re doing badly.<\/p>\n

Expect a lot of takes on the risk section and fewer on the rest. Reviewers listen for clarity and evenness on every word, and they’ll ask for pickups on single phrases where a word got swallowed. Keep your setup steady so those pickups match. Same mic position, same distance, same energy.<\/p>\n

Expect very specific notes. “Slow down on the contraindications.” “A touch more level on the last line.” “Don’t lift at the end of ‘tell your doctor’.” Take them as they come and keep the rest of the read the same. If you’re new to live direction, it helps to remember that they’re adjusting the spot, not judging you.<\/p>\n

Expect confidentiality. Unreleased drugs and campaigns are commercially sensitive. If you’re asked to sign a non disclosure agreement, read it, keep to it, and don’t post about the job until it’s public and the client says you can.<\/p>\n

Usage, rates and the long life of a pharma spot<\/h2>\n

Pharmaceutical ads often run nationally and for a long time, across TV, streaming, radio and online video. That makes the usage terms as important as the session fee.<\/p>\n

Check where the spot will run, for how long, and in which media. A broadcast campaign on national TV is a very different job from an internal training video for sales reps, even if the script looks similar. Our guide to usage rights and who owns your voice after the session<\/a> explains how those terms work and what to look for before you agree.<\/p>\n

Union pharma work in the United States usually falls under SAG-AFTRA’s commercials contracts. If you’re non-union, still quote by usage, media and term rather than as a flat fee, because a national pharma spot can earn its keep for a long time.<\/p>\n

\"A

\u00a9 The Voice Realm<\/p><\/div>\n

What’s coming next for drug ads<\/h2>\n

The rules may change again. In July 2026 the FDA listed a proposed rule called “Transparency in Direct-to-Consumer Advertising” that would remove the adequate provision option. Under that proposal, broadcast ads would have to include the full brief summary of risks rather than pointing viewers elsewhere.<\/p>\n

Writing on the FDA Law Blog, attorneys Dara Katcher Levy and Jeffrey N. Wasserstein noted that “The proposal appears to be set for publication in December 2026.” They also argued that much longer risk sections could make broadcast drug ads too expensive to run, and they expect legal challenges.<\/p>\n

Nobody knows yet how it will play out, and a proposed rule isn’t law. For voice actors there are two possibilities to keep in mind. Risk sections could get much longer, which makes clarity, breath control and stamina even more valuable. Or some advertisers could move money away from TV and radio spots into other formats. Either way, the skill this article is about, reading a long, technical risk section clearly and calmly, isn’t going anywhere.<\/p>\n

If you want pharma and healthcare work, build a short demo that shows exactly that skill: a warm benefit line followed by a clean, even risk section. Then keep an eye on the voice over jobs board<\/a> for healthcare castings, and make sure your profile says you’re comfortable with medical copy.<\/p>\n

Sources: “21 CFR 202.1, Prescription-drug advertisements”<\/a>, Legal Information Institute, Cornell Law School; “FDA Issues Final Rule and FAQ Regarding Direct-to-Consumer Drug Advertising”<\/a>, Faegre Drinker, January 2024; “Coming Soon: Proposed Rule to Remove Adequate Provision (and Ban DTC TV Ads?)”<\/a>, Dara Katcher Levy and Jeffrey N. Wasserstein, FDA Law Blog, July 2026.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

The FDA has rules for how the side effects in a drug ad must sound. What they mean for your read, your script mark-up and your next pharma session.<\/p>\n","protected":false},"author":5,"featured_media":7463,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[36,504],"tags":[562,1058,1059,1055,1056,1057,593],"class_list":["post-7462","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-voice-over-industry","category-voice-over-tips","tag-commercial-voice-over","tag-fda-major-statement","tag-medical-voice-over","tag-pharma-voice-over","tag-pharmaceutical-commercial","tag-side-effects-read","tag-voice-acting-tips"],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t